Hospital leaders must begin preparing for a future shift in transcatheter aortic valve replacement (TAVR) market dynamics as many companies develop devices to enter this market.
Though Edwards Lifesciences’ Sapien Valve remains the only commercially approved TAVR device on the market, Medtronic’s CoreValve will likely gain approval sometime in 2015. Because some European countries are experiencing up to a 25% decrease in TAVR valve cost, the current $30,000 TAVR device price tag may begin to drop as the market opens up. Based on interim trial results that have begun to support TAVR's use in intermediate risk patients, experts think further market expansion is likely.
TAVR poised for further market expansion
Due to increasing cost pressure and decelerating reimbursement, hospital administrators are especially wary of high-cost, niche capital investments. Our researchers examine these technologies carefully—considering patient satisfaction, physician preferences, and downstream repercussions.
The Corindus Vascular Robotics’ CorPath 200, presented at this year’s Cardiovascular Research Technologies (CRT) conference, was one such technology that offered tremendous physician satisfaction but left us wondering, is it really worth the cost?
Robotic PCI: Is it worth the cost?
At the 2013 Cardiovascular Research Technologies (CRT) conference, peripheral arterial disease (PAD) experts presented on a broad range of novel techniques and devices transforming the treatment paradigm. With countless devices on the market geared to treat various forms of the disease, the list of physician preference items continues to grow, driving up device costs for hospitals.
Atherectomy devices: Expensive toys or imperative tools?